移植
医学
干细胞
缓和医疗
重症监护医学
干细胞疗法
生活质量(医疗保健)
梅德林
肿瘤科
疾病
治疗
作者
Amber Feng,Madhuri Gottam,Wil L. Santivasi,Thomas William LeBlanc
标识
DOI:10.1080/14737167.2025.2572317
摘要
INTRODUCTION: Hematopoietic stem cell (HSCT) and chimeric antigen receptor T-cell (CAR-T) therapy are crucial in the treatment of hematologic malignancies. While HSCT has been long established as a mainstay of the treatment of these diseases, CAR-T is a newer therapy with the potential to change the treatment landscape. Both cellular therapies are time and resource intensive, which has put stressors on patients that are unique from those associated with other forms of oncologic treatment. AREAS COVERED: In this review, we discuss the current state of knowledge of psychological symptoms associated with HSCT and CAR-T and their management. In addition, we discuss the models of patient reported outcomes (PROs) used to perform this research. We performed a literature review on PubMed using keywords including 'palliative care, palliative care integration, hematologic malignancy, patient reported outcome, psychological care, and quality of life.' We included papers published before 1 April 2025. EXPERT OPINION: We propose further investigations into integrated models of oncologic and palliative care teams and their efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI